Literature DB >> 10656737

Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis.

K Matsui1, K Takeda, Z X Yu, W D Travis, J Moss, V J Ferrans.   

Abstract

BACKGROUND: Matrix metalloproteinases (MMPs) have been shown to be involved in the pathogenesis of the destructive pulmonary lesions in patients with lymphangioleiomyomatosis (LAM); in the present report, the activation of these enzymes is examined.
OBJECTIVE: To evaluate the role of MMPs and their activating enzymes, immunohistochemical and confocalmicroscopic techniques were used to localize alpha-smooth muscle actin (alpha-SMA), HMB-45, proliferating cell nuclear antigen (PCNA), MMP-2, membrane-type 1 MMP (MT1-MMP), MT2-MMP, and MT3-MMP in lung tissues from 10 women with LAM. Tissue samples were obtained from 5 patients before treatment and in 5 patients after hormone treatment (progesterone and/or tamoxifen citrate).
RESULTS: Staining for alpha-SMA and MMP-2 was present in all the abnormal smooth muscle cells (LAM cells) in both groups. The percentages of PCNA-, MMP-2-, or MT1-MMP-positive LAM cells were much higher in the untreated group than in the treated group, whereas the percentages of HMB-45-reactive LAM cells were similar in both groups. The reactions for MT1-MMP and PCNA were preferentially localized in small spindle-shaped LAM cells; the reaction for HMB-45 was found in large epithelioid LAM cells. Many of the PCNA-positive cells were also positive for MT1-MMP. Staining for MT2-MMP and MT3-MMP was negative.
CONCLUSIONS: This study demonstrates an association between cellular proliferation and the presence of MT1-MMP in LAM cells. The activation of MMP-2 by MT1-MMP may play an important role in the destruction of lung tissue in this disorder.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10656737     DOI: 10.5858/2000-124-0267-RFAOMM

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  46 in total

Review 1.  Sex-specific lung diseases: effect of oestrogen on cultured cells and in animal models.

Authors:  Bosung Shim; Gustavo Pacheco-Rodriguez; Jiro Kato; Thomas N Darling; Martha Vaughan; Joel Moss
Journal:  Eur Respir Rev       Date:  2013-09-01

2.  Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis.

Authors:  Elena A Goncharova; Dmitriy A Goncharov; Poay N Lim; Daniel Noonan; Vera P Krymskaya
Journal:  Am J Respir Cell Mol Biol       Date:  2005-12-30       Impact factor: 6.914

Review 3.  Diffuse Cystic Lung Disease. Part II.

Authors:  Nishant Gupta; Robert Vassallo; Kathryn A Wikenheiser-Brokamp; Francis X McCormack
Journal:  Am J Respir Crit Care Med       Date:  2015-07-01       Impact factor: 21.405

4.  NK cell activating receptor ligand expression in lymphangioleiomyomatosis is associated with lung function decline.

Authors:  Andrew R Osterburg; Rebecca L Nelson; Benyamin Z Yaniv; Rachel Foot; Walter Rf Donica; Madison A Nashu; Huan Liu; Kathryn A Wikenheiser-Brokamp; Joel Moss; Nishant Gupta; Francis X McCormack; Michael T Borchers
Journal:  JCI Insight       Date:  2016-10-06

Review 5.  Minireview: Lymphangioleiomyomatosis (LAM): The "Other" Steroid-Sensitive Cancer.

Authors:  Hen Prizant; Stephen R Hammes
Journal:  Endocrinology       Date:  2016-07-13       Impact factor: 4.736

6.  Involvement of lymphatics in lymphangioleiomyomatosis.

Authors:  Connie G Glasgow; Angelo Taveira-DaSilva; Gustavo Pacheco-Rodriguez; Wendy K Steagall; Katsuya Tsukada; Xiong Cai; Souheil El-Chemaly; Joel Moss
Journal:  Lymphat Res Biol       Date:  2009-12       Impact factor: 2.589

7.  Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.

Authors:  Francis X McCormack; Nishant Gupta; Geraldine R Finlay; Lisa R Young; Angelo M Taveira-DaSilva; Connie G Glasgow; Wendy K Steagall; Simon R Johnson; Steven A Sahn; Jay H Ryu; Charlie Strange; Kuniaki Seyama; Eugene J Sullivan; Robert M Kotloff; Gregory P Downey; Jeffrey T Chapman; MeiLan K Han; Jeanine M D'Armiento; Yoshikazu Inoue; Elizabeth P Henske; John J Bissler; Thomas V Colby; Brent W Kinder; Kathryn A Wikenheiser-Brokamp; Kevin K Brown; Jean F Cordier; Cristopher Meyer; Vincent Cottin; Jan L Brozek; Karen Smith; Kevin C Wilson; Joel Moss
Journal:  Am J Respir Crit Care Med       Date:  2016-09-15       Impact factor: 21.405

8.  Reversible airflow obstruction in lymphangioleiomyomatosis.

Authors:  Angelo M Taveira-DaSilva; Wendy K Steagall; Antoinette Rabel; Olanda Hathaway; Sergio Harari; Roberto Cassandro; Mario Stylianou; Joel Moss
Journal:  Chest       Date:  2009-05-15       Impact factor: 9.410

9.  Faslodex inhibits estradiol-induced extracellular matrix dynamics and lung metastasis in a model of lymphangioleiomyomatosis.

Authors:  Chenggang Li; Xiaobo Zhou; Yang Sun; Erik Zhang; John D Mancini; Andrey Parkhitko; Tasha A Morrison; Edwin K Silverman; Elizabeth P Henske; Jane J Yu
Journal:  Am J Respir Cell Mol Biol       Date:  2013-07       Impact factor: 6.914

10.  Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells.

Authors:  Po-Shun Lee; Szeman W Tsang; Marsha A Moses; Zachary Trayes-Gibson; Li-Li Hsiao; Roderick Jensen; Rachel Squillace; David J Kwiatkowski
Journal:  Am J Respir Cell Mol Biol       Date:  2009-04-24       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.